Emil Wolsk

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Cardiac Resynchronization Therapy

Coronary Artery

Top Venues

Circulation. Heart failure

Journal of the American Heart Association

ESC heart failure

This page only lists publications with an associated author ORCID identifier.

Publications

Emil Wolsk, Mikkel Jürgens, Morten Schou, Mads Ersbøll, Philip Hasbak, Andreas Kjaer, Bo Zerahn, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing, Jens Faber, Caroline Michaela Kistorp, Finn Gustafsson
Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetes. ESC heart failure (2024)
Henning Bundgaard, Anna Axelsson Raja, Kasper Karmark Iversen, Nana Valeur, Niels Tønder, Morten Schou, Alex Hoerby Christensen, Niels Eske Bruun, Helle Søholm, Muzhda Ghanizada, Natasha A S Fry, Elisha J Hamilton, Søren Boesgaard, Mathias B Møller, Emil Wolsk, Kasper Rossing, Lars Valeur Køber, Helge H Rasmussen, Christoffer Rasmus Vissing
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. Circulation. Heart failure 15 (7) (2022)
Emil Wolsk, Brian Lee Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars Køber, Eldrin F Lewis, Aldo Pietro Maggioni, John Joseph Valentine McMurray, Jeffrey L Probstfield, Matthew C Riddle, Scott D Solomon, Jean Claude Tardif, Marc A Pfeffer
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. Journal of the American Heart Association 11 (8) (2022)
Emil Wolsk, Mikkel Jürgens, Morten Schou, Mads Ersbøll, Philip Hasbak, Andreas Kjær, Bo Zerahn, Niels Høgh Brandt, Peter Haulund Gæde, Peter Rossing, Jens Faber, Silvio E Inzucchi, Caroline Michaela Kistorp, Finn Gustafsson
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. Diabetes 71 (4) (2022)